Visit our website for more: https://www.overlookedalpha.com
Moderna stock, quick analysis. Valuation and news of their cancer vaccine.
#stockmarket #investing #stockstobuy #bloomberg #overlookedalpha #shorts
Moderna stock, quick analysis. Valuation and news of their cancer vaccine.
#stockmarket #investing #stockstobuy #bloomberg #overlookedalpha #shorts
Category
🗞
NewsTranscript
00:00 With $17 billion in cash and investments, vaccine pioneer Moderna has a current enterprise
00:05 value around $57 billion. Revenue over the last 12 months was $21.4 billion and net income
00:13 was $11.8 billion. That means the company is valued around 2.7 times revenue or 6.2
00:20 times earnings. That sounds cheap but Moderna's revenue is forecast to fall significantly
00:25 over the next few years as demand for its COVID-19 vaccine declines. According to Standard
00:32 and Poor's, revenue should fall to $8 billion by 2025 and net income to around $2.5 billion.
00:39 More importantly, a few weeks ago Moderna published results of its skin cancer vaccine
00:43 which combined with immunotherapy cut the risk of recurrence or death in high-risk patients
00:49 by 44%. According to the Financial Times, a late-stage melanoma vaccine, if successful,
00:56 could add $5 billion to Moderna's top-line revenue.